Omadacycline
- Generic Name
- Omadacycline
- Brand Names
- Nuzyra
- Drug Type
- Small Molecule
- Chemical Formula
- C29H40N4O7
- CAS Number
- 389139-89-3
- Unique Ingredient Identifier
- 090IP5RV8F
- Background
Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly prob...
- Indication
Omadacycline is indicated for the treatment of community acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by omadacycline-susceptible organisms in adults.
- Associated Conditions
- Acute Bacterial Skin and Skin Structure Infection (ABSSSI), Community-Acquired Bacterial Pneumonia (CABP)
- Associated Therapies
- -
A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Zai Lab (Hong Kong), Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06162286
- Locations
- 🇨🇳
The Third Hospital of Changsha/Respiratory and Critical Care Medicine Department, Changsha, China
🇨🇳Kunming First People's Hospital/Respiratory Medicine, Kunming, China
🇨🇳Shanghai Pulmonary Hospital/Respiratory and Critical Care Medicine Department, Shanghai, China
Microbiome Effect of Omadacycline on Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- University of Houston
- Target Recruit Count
- 32
- Registration Number
- NCT06030219
- Locations
- 🇺🇸
University of Houston, Houston, Texas, United States
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 670
- Registration Number
- NCT04779242
- Locations
- 🇭🇺
Site 803, Debrecen, Hungary
🇧🇬Site 212, Vidin, Bulgaria
🇧🇬Site 206, Ruse, Bulgaria
Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Methodist Health System
- Target Recruit Count
- 600
- Registration Number
- NCT04714411
- Locations
- 🇺🇸
Methodist Dallas Medical Center, Dallas, Texas, United States
🇺🇸Methodist Charlton Medical Center, Dallas, Texas, United States
Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 18
- Registration Number
- NCT04160260
- Locations
- 🇺🇸
Site 106, Doral, Florida, United States
🇺🇸Site 102, San Diego, California, United States
🇺🇸Site 104, San Diego, California, United States
Omadacycline Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis
- Conditions
- Interventions
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Hartford Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT04144374
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 201
- Registration Number
- NCT03757234
- Locations
- 🇬🇪
Site 204, Tbilisi, Georgia
🇱🇻Site 305, Rēzekne, Latvia
🇱🇻Site 304, Liepāja, Latvia
Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI
- Conditions
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 735
- Registration Number
- NCT02877927
- Locations
- 🇺🇸
Site 620, Birmingham, Alabama, United States
🇺🇸Site 606, Buena Park, California, United States
🇺🇸Site 604, Chula Vista, California, United States
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
- Conditions
- Interventions
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 774
- Registration Number
- NCT02531438
- Locations
- 🇵🇪
Site 481, Lima, Peru
🇨🇿Site 411, Praha 10, Czechia
🇧🇬Site 303, Pernik, Bulgaria
Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)
- Conditions
- Interventions
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 655
- Registration Number
- NCT02378480
- Locations
- 🇺🇸
Site 256, Augusta, Georgia, United States
🇺🇸Site 252, Santa Ana, California, United States
🇺🇸Site 259, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.